Literature DB >> 18662707

Psychostimulant-induced alterations in vesicular monoamine transporter-2 function: neurotoxic and therapeutic implications.

Annette E Fleckenstein1, Trent J Volz, Glen R Hanson.   

Abstract

The vesicular monoamine transporter-2 (VMAT-2) is an important regulator of intraneuronal monoamine concentrations and disposition as this protein sequesters critical cytoplasmic monoaminergic transmitters and contributes to their subsequent exocytotic release. This review primarily discusses the impact of psychoactive drugs (including those with abuse potential) on dopamine (DA)-related VMAT-2 and its function. In particular, the different responses by DA-related VMAT-2 and associated vesicles to plasmalemmal uptake blockers like methylphenidate and releasers like methamphetamine are presented. Recent preclinical findings suggest that vesicular transporter systems are highly regulatable, both by changes in localization as well as alterations in the kinetics of the VMAT-2 protein. The capacity for such shifts in VMAT-2 functions suggests the presence of physiological regulation that likely influences the activity of DA systems. In addition, these findings may contribute to our understanding of the pathogenesis of a variety of DA-related disorders such as substance abuse and Parkinson's disease and also suggest new therapeutic targets for treating such diseases.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18662707      PMCID: PMC2634813          DOI: 10.1016/j.neuropharm.2008.07.002

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  60 in total

1.  Sorting of vesicular monoamine transporter 2 to the regulated secretory pathway confers the somatodendritic exocytosis of monoamines.

Authors:  Haiyan Li; Clarissa L Waites; Roland G Staal; Yuriy Dobryy; Jeanna Park; David L Sulzer; Robert H Edwards
Journal:  Neuron       Date:  2005-11-23       Impact factor: 17.173

2.  Methamphetamine administration reduces hippocampal vesicular monoamine transporter-2 uptake.

Authors:  Kristi S Rau; Elisabeth Birdsall; Trent J Volz; James A Riordan; Anthony J Baucum; Brian P Adair; Rebecca Bitter; James W Gibb; Glen R Hanson; Annette E Fleckenstein
Journal:  J Pharmacol Exp Ther       Date:  2006-05-10       Impact factor: 4.030

3.  Kinetic analysis of developmental changes in vesicular monoamine transporter-2 function.

Authors:  Trent J Volz; Glen R Hanson; Annette E Fleckenstein
Journal:  Synapse       Date:  2006-11       Impact factor: 2.562

4.  Bupropion increases striatal vesicular monoamine transport.

Authors:  Kristi S Rau; Elisabeth Birdsall; Jarom E Hanson; Kamisha L Johnson-Davis; F Ivy Carroll; Diana G Wilkins; James W Gibb; Glen R Hanson; Annette E Fleckenstein
Journal:  Neuropharmacology       Date:  2005-07-07       Impact factor: 5.250

Review 5.  Mechanisms of neurotransmitter release by amphetamines: a review.

Authors:  David Sulzer; Mark S Sonders; Nathan W Poulsen; Aurelio Galli
Journal:  Prog Neurobiol       Date:  2005-04       Impact factor: 11.685

6.  Age-dependent methamphetamine-induced alterations in vesicular monoamine transporter-2 function: implications for neurotoxicity.

Authors:  Jannine G Truong; Diana G Wilkins; Jakub Baudys; Dennis J Crouch; Kamisha L Johnson-Davis; James W Gibb; Glen R Hanson; Annette E Fleckenstein
Journal:  J Pharmacol Exp Ther       Date:  2005-05-18       Impact factor: 4.030

Review 7.  Vesicular monoamine transporter 2: role as a novel target for drug development.

Authors:  Guangrong Zheng; Linda P Dwoskin; Peter A Crooks
Journal:  AAPS J       Date:  2006-11-10       Impact factor: 4.009

8.  Measurement of kinetically resolved vesicular dopamine uptake and efflux using rotating disk electrode voltammetry.

Authors:  Trent J Volz; Glen R Hanson; Annette E Fleckenstein
Journal:  J Neurosci Methods       Date:  2006-02-09       Impact factor: 2.390

9.  Augmentation of methamphetamine-induced toxicity in the rat striatum by unpredictable stress: contribution of enhanced hyperthermia.

Authors:  Despina A Tata; Jamie Raudensky; Bryan K Yamamoto
Journal:  Eur J Neurosci       Date:  2007-08       Impact factor: 3.386

10.  Cognitive function and nigrostriatal markers in abstinent methamphetamine abusers.

Authors:  Chris-Ellyn Johanson; Kirk A Frey; Leslie H Lundahl; Pamela Keenan; Nancy Lockhart; John Roll; Gantt P Galloway; Robert A Koeppe; Michael R Kilbourn; Trevor Robbins; Charles R Schuster
Journal:  Psychopharmacology (Berl)       Date:  2006-03-03       Impact factor: 4.530

View more
  43 in total

1.  The effect of a novel VMAT2 inhibitor, GZ-793A, on methamphetamine reward in rats.

Authors:  Joshua S Beckmann; Emily D Denehy; Guangrong Zheng; Peter A Crooks; Linda P Dwoskin; Michael T Bardo
Journal:  Psychopharmacology (Berl)       Date:  2011-09-21       Impact factor: 4.530

2.  Prior methamphetamine self-administration attenuates serotonergic deficits induced by subsequent high-dose methamphetamine administrations.

Authors:  Lisa M McFadden; Madison M Hunt; Paula L Vieira-Brock; Janice Muehle; Shannon M Nielsen; Scott C Allen; Glen R Hanson; Annette E Fleckenstein
Journal:  Drug Alcohol Depend       Date:  2012-05-28       Impact factor: 4.492

3.  Methamphetamine alters vesicular monoamine transporter-2 function and potassium-stimulated dopamine release.

Authors:  Pei-Wen Chu; Gregory C Hadlock; Paula Vieira-Brock; Kristen Stout; Glen R Hanson; Annette E Fleckenstein
Journal:  J Neurochem       Date:  2010-08-25       Impact factor: 5.372

Review 4.  HIV-1 gp120 and drugs of abuse: interactions in the central nervous system.

Authors:  Peter S Silverstein; Ankit Shah; James Weemhoff; Santosh Kumar; D P Singh; Anil Kumar
Journal:  Curr HIV Res       Date:  2012-07       Impact factor: 1.581

5.  A tyrosine-based motif localizes a Drosophila vesicular transporter to synaptic vesicles in vivo.

Authors:  Anna Grygoruk; Hao Fei; Richard W Daniels; Bradley R Miller; Aaron Diantonio; David E Krantz
Journal:  J Biol Chem       Date:  2010-01-06       Impact factor: 5.157

6.  Methamphetamine Induces Dopamine Release in the Nucleus Accumbens Through a Sigma Receptor-Mediated Pathway.

Authors:  David M Hedges; J Daniel Obray; Jordan T Yorgason; Eun Young Jang; Vajira K Weerasekara; Joachim D Uys; Frederick P Bellinger; Scott C Steffensen
Journal:  Neuropsychopharmacology       Date:  2017-11-29       Impact factor: 7.853

Review 7.  Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation.

Authors:  Mahmoud M Iravani; Peter Jenner
Journal:  J Neural Transm (Vienna)       Date:  2011-09-01       Impact factor: 3.575

8.  N-terminus regulation of VMAT2 mediates methamphetamine-stimulated efflux.

Authors:  B Torres; A E Ruoho
Journal:  Neuroscience       Date:  2013-12-07       Impact factor: 3.590

9.  Chronic methylphenidate treatment enhances striatal dopamine neurotransmission after experimental traumatic brain injury.

Authors:  Amy K Wagner; Laura L Drewencki; Xiangbai Chen; F Ryan Santos; Amina S Khan; Rashed Harun; Gonzalo E Torres; Adrian C Michael; C Edward Dixon
Journal:  J Neurochem       Date:  2008-12-10       Impact factor: 5.372

Review 10.  Pharmacotherapy of amphetamine-type stimulant dependence: an update.

Authors:  Matthew Brensilver; Keith G Heinzerling; Steven Shoptaw
Journal:  Drug Alcohol Rev       Date:  2013-04-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.